Why a single negative result hasn't diminished rapamycin's longevity promise

The first clinical trial combining rapamycin with exercise has delivered underwhelming results, yet this setback has not eroded researcher confidence in this immunosuppressant's potential as a geroprotector. Rapamycin works by inhibiting mTOR, a central pathway in aging and metabolic regulation, which explains why it has captivated longevity researchers for over a decade. Though a single negative trial might discourage many, the inherent complexity of human aging and the confounding variables in exercise studies suggest that this combined intervention's failure does not foreclose other protocol designs. For biohackers and clinicians tracking this research frontier, the takeaway is unambiguous: one negative result does not invalidate a strategy, especially when the underlying biological mechanism remains sound.